Abstract CT094: Durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): Outcomes by PD-L1 expression in ADRIATIC

杜瓦卢马布 医学 肿瘤科 内科学 阶段(地层学) 放化疗 安慰剂 癌症 病理 免疫疗法 生物 古生物学 替代医学 无容量
作者
Christine L. Hann,Ying Cheng,David R. Spigel,Byoung Chul Cho,Jian Fang,Yuanbin Chen,Yoshitaka Zenke,Qiming Wang,Reyes Bernabé,John Wen-Cheng Chang,Sema Sezgin Göksu,Lin Wu,Gyeong‐Won Lee,Michael J. Thomas,Y. Ohe,Frank Griesinger,Leah Szadkowski,Hema Gowda,Yashaswi Shrestha,Suresh Senan
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:85 (8_Supplement_2): CT094-CT094 被引量:1
标识
DOI:10.1158/1538-7445.am2025-ct094
摘要

Abstract Background: At the first planned interim analysis of the phase 3 ADRIATIC study (NCT03703297), consolidation D significantly improved the dual primary endpoints of overall survival (OS; HR 0.73; 95% CI 0.57-0.93; p=0.0104) and progression-free survival (PFS; HR 0.76; 95% CI 0.61-0.95; p=0.0161) vs P in patients (pts) with LS-SCLC with no progression after cCRT. Although PD-L1 is not currently a validated immunotherapy biomarker in SCLC (unlike NSCLC) and is generally expressed at low levels in this setting, PD-L1 was evaluated as a potential biomarker in ADRIATIC. Methods: Pts with stage I-III LS-SCLC (stage I/II inoperable), WHO performance status 0/1, and no progression after cCRT, were randomized 1-42 days post cCRT to D (n=264), D + tremelimumab (n=200; arm remains blinded), or P (n=266). The VENTANA PD-L1 (SP263) immunohistochemistry assay was used for central retrospective testing of pre-cCRT tissue samples. OS and PFS were assessed in the PD-L1-evaluable population and in subgroups with PD-L1 expression ≥1% on tumor cells (TC) and/or immune cells (IC) (secondary endpoint) and <1% on TC and IC (data cutoff: Jan 15, 2024). Results: Among 162 (61.4%) and 171 (64.3%) pts in the D and P arms who were evaluable for PD-L1, improvements in OS (HR [D vs P] 0.73 [95% CI 0.53-0.99]) and PFS (HR 0.80 [0.60-1.06]) were of similar magnitude to those in the ITT population. Of the PD-L1-evaluable pts, 51.9% (84/162) in the D arm and 57.3% (98/171) in the P arm had PD-L1 TC or IC ≥1%. D appeared to improve OS and PFS vs P in subgroups with TC or IC ≥1% and with TC and IC <1% (Table), consistent with the ITT population. Conclusions: Among the PD-L1-evaluable population in ADRIATIC, 54.7% (182/333) of pts had PD-L1 TC or IC ≥1%. Consolidation D appeared to improve OS and PFS vs P irrespective of PD-L1 expression based on a cutoff of 1% on TC and/or IC, further supporting consolidation D as the new standard of care in pts with LS-SCLC with no progression after cCRT. Citation Format: Christine Hann, Ying Cheng, David Spigel, Byoung Chul Cho, Jian Fang, Yuanbin Chen, Yoshitaka Zenke, Qiming Wang, Reyes Bernabe, John Wen-Cheng Chang, Sema Sezgin Goksu, Lin Wu, Gyeong-Won Lee, Michael Thomas, Yuichiro Ohe, Frank Griesinger, Leah Szadkowski, Hema Gowda, Yashaswi Shrestha, Suresh Senan. Durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC): Outcomes by PD-L1 expression in ADRIATIC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT094.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lyx5266发布了新的文献求助10
刚刚
1秒前
ccdw发布了新的文献求助10
1秒前
2秒前
2秒前
阿泽发布了新的文献求助10
2秒前
大尾猫完成签到 ,获得积分10
3秒前
在水一方的应助被风中的宛白采纳,获得10
3秒前
carol0705发布了新的文献求助10
4秒前
愉快小凝发布了新的文献求助10
4秒前
5秒前
FashionBoy的应助被QQ采纳,获得10
5秒前
可爱的函函的应助被mm采纳,获得10
5秒前
木青完成签到,获得积分10
6秒前
Voiceless的应助被专注的半雪采纳,获得50
6秒前
7秒前
武子阳完成签到 ,获得积分10
7秒前
阿泽完成签到,获得积分10
8秒前
健忘映寒完成签到,获得积分10
8秒前
完美世界的应助被Heven88采纳,获得10
8秒前
8秒前
完美世界的应助被源宥冰采纳,获得10
9秒前
10秒前
shilong.yang发布了新的文献求助10
10秒前
angki77发布了新的文献求助10
11秒前
天天快乐的应助被过时的文博采纳,获得10
12秒前
py发布了新的文献求助10
12秒前
13秒前
斯文败类的应助被Mao采纳,获得10
13秒前
科研通AI6.4的应助被ccdw采纳,获得10
15秒前
晴慕紫晓完成签到,获得积分10
15秒前
15秒前
15秒前
lll发布了新的文献求助10
15秒前
angki77完成签到,获得积分10
16秒前
万荼巳蕊发布了新的文献求助10
17秒前
17秒前
辛道月完成签到 ,获得积分10
18秒前
18秒前
flower完成签到 ,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181408
求助须知:如何正确求助?哪些是违规求助? 9571330
关于积分的说明 21817615
捐赠科研通 7777856
什么是DOI,文献DOI怎么找? 3433479
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479527